Charles River Laboratories International, Inc. CRL
292.84
(1.60)
(0.54%)
as of 25 Sep
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Charles River Laboratories International, Inc. (CRL) Return on equity
Charles River Laboratories International, Inc.'s return on equity over the twelve months to 30 June 2026 was −7.69%, down 3.3 percentage points from fiscal 2025 (−4.35%). Over the past ten years it has ranged from −4.35% (fiscal 2025) to 21.1% (fiscal 2015) — the current reading is the lowest in ten years. That is below the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −4.35% | (4.64) |
| FY2024 | 0.29% | (14.13) |
| FY2023 | 14.4% | (3.20) |
| FY2022 | 17.6% | 0.83 |
| FY2021 | 16.8% | (2.61) |
| FY2020 | 19.4% | 2.36 |
| FY2019 | 17.0% | (2.09) |
| FY2018 | 19.1% | 6.05 |
| FY2017 | 13.1% | (6.55) |
| FY2016 | 19.6% | (1.50) |
Against its own ten years
Low −4.35%
High 21.1%
Ten-year median
17.0%
Current reading's percentile
9
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 171.6% |
| MEDP Medpace Holdings, Inc. compare | 162.2% |
| DGX Quest Diagnostics Incorporated compare | 14.0% |
| QGEN QIAGEN N.V. compare | 11.9% |
| LH Labcorp Holdings Inc. compare | 11.7% |
| RVTY Revvity Inc. compare | 3.21% |
| ICLR ICON PLC compare | 0.45% |
| CRL Charles River Laboratories International, Inc. | −7.69% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| Diagnostics & Research industry median | −2.92% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement